Geoffrey R. Oxnard, MD

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Publications

  • Published 1/3/2026

    Battaglini J, AlDoughaim M, Li K, Patel J, Bhatt S, Everett P, Oxnard GR, Tapan U. Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer. Clin Transl Oncol. 2026 Jan 03. PMID: 41484568.

    Read at: PubMed

  • Published 12/1/2025

    Shord SS, Chen C, Jin JY, Van Wart S, Martin SK, Davidson BA, Liu J, LoRusso PM, Oxnard GR. FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials. Clin Cancer Res. 2025 Dec 01; 31(23):4891-4898. PMID: 41036557.

    Read at: PubMed

  • Published 11/29/2025

    Burns TF, Ammakkanavar NR, Hollebecque A, Lee DH, Koyama T, Cassier PA, Italiano A, Han JY, Singhal N, Takeuchi S, Heist RS, Deming D, Spira A, Chu Q, Sacher A, Fujiwara Y, Chisamore MJ, You AX, McNeely SC, Fink A, Chen A, Oxnard GR, Willard MD, Murciano-Goroff YR, Dragnev KH. Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC. J Thorac Oncol. 2026 Apr; 21(4):103528. PMID: 41319864.

    Read at: PubMed

  • Published 6/13/2025

    Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA. Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. Clin Cancer Res. 2025 Jun 13; 31(12):2406-2412. PMID: 39887260.

    Read at: PubMed

  • Published 6/3/2025

    Andrews HS, Zariffa N, Nishimura KK, Choi SH, Deng S, Eisele M, Espenschied CR, Goren EM, Guha M, Hong S, Juraeva D, Krämer N, Liu L, Martini JF, McKelvey BA, Oxnard GR, Pestano GA, Poole L, Rosenthal A, Szpurka AM, Vega DM, Ward C, Wijayawardana SR, Hoering A, Stewart MD, Allen JD. ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials. Clin Cancer Res. 2025 Jun 03; 31(11):2162-2172. PMID: 40261185.

    Read at: PubMed

View All 214 Publications:   View Full Profile in BUMC

Websites

Education

  • University of Chicago, MD
  • Harvard University, AB

View all profiles